GRI BIO, Inc. Files 8-K on Security Holder Votes
Ticker: GRI · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1824293
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
Related Tickers: GRIB
TL;DR
GRI BIO (GRIB) filed an 8-K for shareholder votes - governance in action.
AI Summary
GRI BIO, Inc. filed an 8-K on August 23, 2024, to report on matters submitted to a vote of its security holders. The company, formerly known as Vallon Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates that GRI BIO, Inc. is engaging in corporate governance activities requiring shareholder approval, which can impact the company's strategic direction and operational decisions.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not immediately present new financial or operational risks.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- August 23, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of GRI BIO, Inc.'s security holders?
The filing states that the 8-K is for the 'Submission of Matters to a Vote of Security Holders,' but the specific details of these matters are not provided in the excerpt.
When was GRI BIO, Inc. formerly known as Vallon Pharmaceuticals, Inc.?
The date of the name change from Vallon Pharmaceuticals, Inc. to GRI BIO, Inc. was September 10, 2020.
What is the primary business of GRI BIO, Inc. according to its SIC code?
GRI BIO, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are GRI BIO, Inc.'s principal executive offices located?
The principal executive offices of GRI BIO, Inc. are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the fiscal year end for GRI BIO, Inc.?
The fiscal year end for GRI BIO, Inc. is December 31 (1231).
Filing Stats: 657 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-08-23 16:05:11
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20240823.htm (8-K) — 24KB
- val-20240823_g1.jpg (GRAPHIC) — 16KB
- val-20240823_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000116.txt ( ) — 176KB
- val-20240823.xsd (EX-101.SCH) — 2KB
- val-20240823_lab.xml (EX-101.LAB) — 22KB
- val-20240823_pre.xml (EX-101.PRE) — 13KB
- val-20240823_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On August 23, 2024, GRI Bio, Inc. (the "Company") convened and then adjourned its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Company previously filed a Definitive Proxy Statement, dated August 2, 2024, as amended and supplemented to date (as amended and supplemented, the "Proxy Statement"). A total of 741,914 shares of the Company's common stock were entitled to vote on June 27, 2024, the record date for the Annual Meeting, and 256,566 shares of common stock, or approximately 34.58% of the shares entitled to vote, were present or represented by proxy at the Annual Meeting. Per the Company's amended and restated bylaws, a quorum requires the presence, in person or by proxy, of the holders of one-third of the voting power of the stock outstanding and entitled to vote at the Annual Meeting. As a result, there was a quorum present for the Annual Meeting. The only matter submitted to a vote of stockholders at the Annual Meeting was the proposal regarding adjournment of the Annual Meeting as further described in Proxy Statement, and the voting results for this proposal are set forth below. After the vote on this adjournment proposal, the Company adjourned the Annual Meeting to Friday, September 6, 2024 at 11:00 a.m., Eastern Time, virtually at www.virtualshareholdermeeting.com/GRI2024 to allow for the solicitation of additional proxies to adopt the remaining proposals set forth in the Proxy Statement for the Annual Meeting. Adjournment Proposal The proposal to approve any postponement or adjournment of the Annual Meeting, from time to time, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to adopt the proposals set forth in the proxy statement or to establish a quorum was approved as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 157,455 99,095 16 —
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 23, 2024 GRI Bio, Inc. By: /s/ Leanne Kelly Leanne Kelly Chief Financial Officer